Please login to the form below

Not currently logged in

CDK4/6 inhibitor

This page shows the latest CDK4/6 inhibitor news and features for those working in and with pharma, biotech and healthcare.

FDA approves Eli Lilly’s Verzenio in high risk early breast cancer

FDA approves Eli Lilly’s Verzenio in high risk early breast cancer

Over time, the collective results of the Verzenio clinical development programme have demonstrated a differentiated CDK4/6 inhibitor profile, and the landmark data from the monarchE trial that supported this new ... Verzenio is the first and only CDK4/6

Latest news

More from news
Approximately 2 fully matching, plus 30 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....